Related Experiment Video

Updated: Aug 8, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Therapeutic potential of angiotensin receptor blockers in hypertension

Bernard M Y Cheung1

  • 1University of Hong Kong, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong. mycheung@hkucc.hku.hk

Expert Opinion on Investigational Drugs
|May 31, 2006
PubMed

Insights

Angiotensin II receptor blockers (ARBs) effectively treat cardiovascular diseases like hypertension and heart failure. These well-tolerated drugs offer an alternative for patients unable to use ACE inhibitors, requiring renal and electrolyte monitoring.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The renin-angiotensin-aldosterone system is crucial for fluid and electrolyte balance.
  • Angiotensin II receptor blockers (ARBs) target angiotensin II type 1 receptors.

Purpose of the Study:

  • To review the efficacy and tolerability of ARBs in cardiovascular diseases.
  • To highlight ARBs as a treatment option for hypertension and related conditions.

Main Methods:

  • Review of large clinical trials on ARBs.
  • Analysis of ARB effectiveness in hypertension, heart failure, myocardial infarction, and diabetic nephropathy.

Main Results:

  • ARBs demonstrate significant efficacy in managing hypertension and other cardiovascular conditions.
  • ARBs are well-tolerated, suitable for monotherapy or combination treatment.
  • ARBs are particularly beneficial for hypertensive patients with comorbidities like diabetes and heart failure.
  • ARBs do not cause the persistent dry cough associated with ACE inhibitors.

Conclusions:

  • ARBs are effective and well-tolerated agents for cardiovascular diseases, especially hypertension.
  • ARBs are a valuable alternative for patients intolerant to ACE inhibitors.
  • Regular monitoring of renal function and electrolytes is necessary during ARB therapy.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...